Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05178784 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EEG Biomarker Study for Participants in the Neurolief "MOOD" Trial

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Nov 16, 2024 to Dec 3, 2024
    • Study completion date: Nov 16, 2024 to Nov 16, 2025
    v6
  2. Trial status: Enrolling by Invitation to Active, Not Recruitingv5
  3. Primary and study completion dates: Nov 16, 2023 to Nov 16, 2024v4
  4. 2 versions Re-verified since Jan 5, 2022, no change to tracked fieldsv2-v3
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Butler Hospital
30 trials monitored
See 1 trial at risk
Depression
3,055 trials monitored
See 173 trials at risk
This study will collect EEG data at 3 time points from up to 40 adults who are enrolled in a double clinical trial investigating a device that delivers noninvasive, self-administered external Combined Occipital and Trigeminal Neurostimulation (eCOT-NS) treatment for Major Depressive Disorder (Relivion®DP). Baseline (Pre-treatment) Frontal EEG Alpha Oscillations (Power) will be compared post-stimulation power.
Trial Details
NCT Number NCT05178784
Lead Sponsor Butler Hospital
Collaborators: Neurolief Ltd., University of North Carolina, Chapel Hill
Conditions
(from sponsor)		 Depression
Related terms Depression
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov